Oligometastatic Lung Adenocarcinoma
Conditions
Keywords
Sensitizing EGFR Mutations, Erlotinib, Surgery, Radiation Therapy, 15-067
Brief summary
This study will test if local therapies in addition to erlotinib can improve responses and delay the time until new treatment is required. This study will also collect blood samples for research blood tests.
Interventions
DRUGErlotinib
OTHERLocal Therapies
Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed metastatic lung adenocarcinoma (recurrent or de novo) harboring sensitizing EGFR mutations (L858R, exon 19 deletion, G719A, L861Q, S768I, exon 19 insertions) with oligometastatic disease (≤5 discrete lesions of disease irrespective of location, inclusive of the primary lesion): * all sites of disease must be amenable to definitive treatment with a local therapy (surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy) as determined by surgery, interventional radiology and radiation oncology * all intrathoracic lymph nodes (including hilar, mediastinal, and supraclavicular nodal disease) are considered 1 discrete lesion. * Each brain metastasis is included as a distinct lesion. * Patients already started on erlotinib are eligible as long as their sites of disease are determined to be eligible for definitive local therapy by consensus of the principal investigators within 12 weeks of the patient first taking erlotinib. * Lung adenocarcinoma histology confirmed at MSKCC. * Available archived tissue to perform molecular analysis * Patients without available archived tissue can have repeat biopsies to determine EGFR status as per standard clinical care guidelines * Age 18 years or older * Karnofsky Performance Status ≥ 70% * Adequate bone marrow, liver and renal function, as specified below: * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L * Hemoglobin ≥ 8 g/dL * Platelets ≥ 100 x 109/L * Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome) * AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present * Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal. * For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment * Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter
Exclusion criteria
* Treatment with erlotinib prior to developing metastatic disease * Patients with activating but not sensitizing mutations (exon 20 insertions, EGFR T790M) * Malignant pleural effusion or pleural disease * Leptomeningeal disease * Any site of disease that is not amenable to definitively local therapy including surgery or radiation therapy * Women who are breastfeeding or pregnant * Concurrent malignancies other than non-melanoma skin cancer that require active ongoing treatment. * Any medical co-morbidities that would preclude surgery or radiation therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy. | 2 years | At least five patients will need to complete local therapy within 2 years of the study being open to accrual for the primary endpoint to be met. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Oligometastatic Non-Small Cell Lung Cancer Patients will be placed on EGFR-TKI for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will undergo induction TKI for 12 weeks. At the conclusion of 12 weeks on erlotinib, patients without disease progression \[partial response (PR) or stable disease (SD)\] will undergo definitive local treatment to all remaining sites of disease. After local therapy, erlotinib will be resumed until progression of disease (POD) by RECIST criteria. All assessments completed during the 12 week TKI induction phase are to be performed per protocol with a ± 7 day window. | 4 |
| Total | 4 |
Baseline characteristics
| Characteristic | Oligometastatic Non-Small Cell Lung Cancer |
|---|---|
| Age, Continuous | 61 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 2 Participants |
| Region of Enrollment United States | 4 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 4 |
| other Total, other adverse events | 3 / 4 |
| serious Total, serious adverse events | 1 / 4 |
Outcome results
Primary
Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy.
At least five patients will need to complete local therapy within 2 years of the study being open to accrual for the primary endpoint to be met.
Time frame: 2 years
Population: Primary outcome accrual goal was not achieved. Data were not collected.